Halda Therapeutics
David Puleo has a diverse work experience in the field of scientific research and development. David started their career at Novartis Institutes for BioMedical Research (NIBR), where they worked as a Scientific Associate I from June 2010 to May 2011 and later as a Scientific Associate II from June 2011 to July 2012. David then joined Yale University in August 2012 as a Ph.D. Candidate and worked there until October 2018. During their time at Yale, they also served as a Postdoctoral Associate from November 2018 to February 2019. In February 2019, David joined Halda Therapeutics as a Senior Research Scientist and worked there until September 2020. David then transitioned to the role of Research Investigator at Halda Therapeutics from October 2020 to October 2022. Currently, David is working as the Principal Scientist at Halda Therapeutics since November 2022.
David Puleo completed their Bachelor of Science degree in Biochemistry at Boston College from 2006 to 2010. Following this, they pursued their Doctor of Philosophy (PhD) in Pharmacology at Yale University, where they studied from 2012 to 2018.
This person is not in the org chart
Halda Therapeutics
1 followers
Halda is inventing novel precision medicines for oncology. Specifically, we are developing RIPTAC™ therapeutics, a new drug modality for the treatment of cancer. Founded by world renowned Yale scientist, Professor Craig Crews, Halda invented RIPTAC therapeutics as an innovative cancer treatment approach that does not rely on traditional oncogenic disease drivers to target cancer. This powerful technology is designed to overcome the known bypass mechanisms of drug resistance, a common limitation of today’s precision cancer medicines. Using a novel ‘hold and kill’ mechanism, RIPTAC therapeutics target cancer cells selectively by bringing two proteins together in a tightly regulated manner, causing the loss of an essential function for cell survival and subsequent cancer cell death. We have built a pipeline of RIPTAC therapeutics for major cancer types, uniquely addressing the unmet needs of drug resistant cancer patients, and we will continue to invent new medicines using our proprietary platform technology. We are a bold company where collaboration, passion, and creativity thrive, all of which allows us to push the boundaries of drug discovery to identify better solutions. Halda is proud to be a New Haven, CT based biotech, located with headquarters and state-of-the-art labs in Science Park.